BioAxone is poised to revolutionize therapies for traumatic CNS injuries. Through a combination of non-dilutive SBIR grants totaling in excess of $1M and attractive up-front payments and future milestones from our development partner Vertex Pharmaceuticals, Inc., we have grown an attractive clinical and pre-clinical product pipeline with product candidates addressing 100’s of thousands of patients with no currently available therapies for their conditions.

BioAxone is building on the following value:

  • Experienced management – Well balanced development team
  • World class scientific and clinical advisors
  • Exceptional clinical results showing safety and efficacy of Cethrin™ for SCI treatment
  • Validated  science
  • Over 14 issued patents (US and Global)
  • Newly established partnership with Vertex
  • Understanding of translational medicine to bring new drugs forward to clinical testing
  • Successful NIH/SBIR funding and a strong pipeline

For direct information on investment opportunities, please contact:

Dr. Lisa McKerracher Chief Executive Officer, BioAxone (617) 401 3115